Zistite viac o príležitostiach v spoločnosti Novartis. Pre ďalšie pracovné ponuky v Novartis Gene Therapies (predtým AveXis) navštívte GTx Career Search . Oznámenie pre uchádzačov o voľné pracovné ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Lediga tjänster Bli en del av Novartis, här kan du se mer om vilka karriärmöjligheter som finns.

First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...

Learn about Novartis annual results, including media releases, annual reports, webcasts and presentations, and year-to-date figures.

The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse ...

A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment with the product. By reporting side effects ...

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...

Novartis Pharmaceuticals Corporation (“Novartis”), in cooperation with the U.S. Consumer Product Safety Commission (“CPSC”) and Food and Drug Administration (“FDA”), is voluntarily implementing a CPSC ...